Lacosamidewas recently approved as an antiepileptic drug by the United Statesand European Union. Lacosamideis used as an adjunctive therapy in the treatment of intractable partial-onset seizures in patients 16-17 years of age and older. Lacosamide introduced to Ali Askar Hospital, Tripoli-Libya, in tablet (50-100mg)and syrup dosage forms (10mg/ml).This study was performedon 61 patients (between the years of 2013 to 2015).The purpose of this study was to evaluate the safety and efficacy of oral lacosamideadministration as a concomitant therapy with multiple antiepileptic drugs (AEDs) with intractable epilepsy.Seizure frequency for patients with intractable partial epilepsy were recorded and compared to the seizure frequency after adding lacosamide to their prior treatment regimen. 74 % had reduction in seizure frequency with lacosamide and (5%) of seizure freedom. The non-responders to lacosamide were13%. While another 13% get worse with this drug. Complex partial seizures recorded the highest ratio in this study according to the type of seizures. In conclusion, adjunctive lacosamide was safe, efficacious, well tolerated and dramatically reduced seizures in patients with intractable epilepsy who had failed by otherAEDs. However, epilepsy still can be controlled but not totally cured.